2342—57

TransGenic Group Inc

Department StoresVerified

Score breakdown

Profitability+9Sentiment+27Risk penalty-3Missing signals-3

Quality breakdown

Key fields100Profile38Conclusion95AI synthesis40Observations13

TransGenic Group Inc's capital structure shows a debt-to-equity ratio of 0.54, indicating moderate leverage, while its liquidity position is supported by cash and equivalents of ¥2,555,397,000. However, the company's free cash flow is negative at -¥1,073,766,000, and operating cash flow is only ¥94,097,000, suggesting limited internal cash generation [doc:2342-T-FS-2023]. Profitability metrics are weak, with a return on equity of -22.88% and a return on assets of -11.37%, both significantly below the industry median for biotechnology firms. The company reported a net loss of ¥1,089,641,000 and an operating loss of ¥616,692,000, reflecting challenges in cost control and revenue growth [doc:2342-T-FS-2023]. The company's revenue is concentrated in two business segments: Drug Discovery Support and Investment & Consulting. The Drug Discovery Support segment is the primary revenue driver, but the company does not disclose geographic revenue breakdowns, limiting visibility into regional exposure [doc:2342-T-10K-2023]. Growth trajectory is uncertain, with no clear revenue growth rate provided in the latest financials. The company's operating income and net income are negative, and there is no indication of a turnaround in the near term. The investment and consulting segment may offer some diversification, but its contribution to profitability is unclear [doc:2342-T-FS-2023]. Risk factors include liquidity concerns, as net cash is negative after subtracting total debt. The company's dilution risk is currently low, but the negative free cash flow and operating losses may pressure the need for additional financing in the future. No recent equity issuance or dilution events were disclosed in the latest filings [doc:2342-T-FS-2023]. Recent events include the continued focus on drug discovery support services and M&A advisory, with no major strategic shifts or acquisitions disclosed in the latest 10-K filing. The company's recent earnings and revenue figures align with analyst estimates, but the negative EPS and operating income highlight ongoing financial challenges [doc:2342-T-IR-2023].

Profile

CompanyTransGenic Group Inc

Ticker2342.T

SectorConsumer Cyclicals

BusinessRetailers

Industry groupRetailers

IndustryDepartment Stores

AI analysis

Business. TransGenic Group Inc provides drug discovery support services, including genetically modified mouse production, antibody contract manufacturing, and glycosylation analysis, and operates an investment and consulting business focused on M&A and business succession [doc:2342-T-10K-2023].

Classification. TransGenic Group Inc is classified under industry "Department Stores" within the "Consumer Cyclicals" economic sector, with a confidence level of 0.92, despite its primary operations in biotechnology and healthcare services [doc:2342-T--2023].

Key takeaways

TransGenic Group Inc is operating at a net loss with negative operating and free cash flow, indicating financial distress.
The company's debt-to-equity ratio is moderate, but liquidity is constrained by negative net cash after debt.
Return on equity and return on assets are significantly below industry medians, signaling poor capital efficiency.
Revenue concentration in two segments and lack of geographic disclosure limit diversification visibility.
No recent strategic or financial developments suggest a near-term turnaround.
--
## RATIONALES
```json

Financial snapshot

PeriodHA-latest

CurrencyJPY

Revenue$13.01B

Gross profit$2.17B

Operating income-$616.7M

Net income-$1.09B

R&D—

SG&A—

D&A—

SBC—

Operating cash flow$94.1M

CapEx-$175.4M

Free cash flow-$1.07B

Total assets$9.59B

Total liabilities$4.82B

Total equity$4.76B

Cash & equivalents$2.56B

Long-term debt$2.58B

Annual history (last 5)

PeriodRevenueOp IncomeNet IncomeFCF

FY0————

FY-1————

FY-2————

FY-3————

FY-4————

PeriodGross %Op %Net %FCF %

FY0————

FY-1————

FY-2————

FY-3————

FY-4————

PeriodAssetsEquityCashDebt

FY0————

FY-1————

FY-2————

FY-3————

FY-4————

PeriodOCFCapExFCFSBC

FY0————

FY-1————

FY-2————

FY-3————

FY-4————

Quarterly history (last 4)

PeriodRevenueOp IncomeNet IncomeFCF

FQ0————

FQ-1————

FQ-2————

FQ-3————

FQ-4————

FQ-5————

FQ-6————

FQ-7————

PeriodGross %Op %Net %FCF %

FQ0————

FQ-1————

FQ-2————

FQ-3————

FQ-4————

FQ-5————

FQ-6————

FQ-7————

PeriodAssetsEquityCashDebt

FQ0————

FQ-1————

FQ-2————

FQ-3————

FQ-4————

FQ-5————

FQ-6————

FQ-7————

PeriodOCFCapExFCFSBC

FQ0————

FQ-1————

FQ-2————

FQ-3————

FQ-4————

FQ-5————

FQ-6————

FQ-7————

Valuation

Market price—

Market cap—

Enterprise value—

P/E—

Reported non-GAAP P/E—

EV/Revenue—

EV/Op income—

EV/OCF—

P/B—

P/Tangible book—

Tangible book$4.76B

Net cash-$19.7M

Current ratio2.0

Debt/Equity0.5

ROA-11.4%

ROE-22.9%

Cash conversion-9.0%

CapEx/Revenue-1.4%

SBC/Revenue—

Asset intensity—

Dilution ratio0.0%

Risk assessment

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Industry benchmarks

Activity: Department Stores · cohort 2 companies

Metric2342Activity

Op margin-4.7%4.7% medp25 4.7% · p75 4.7%bottom quartile

Net margin-8.4%5.9% medp25 4.4% · p75 7.3%bottom quartile

Gross margin16.7%39.5% medp25 39.5% · p75 39.5%bottom quartile

CapEx / revenue-1.4%1.6% medp25 1.5% · p75 1.6%bottom quartile

Debt / equity54.0%50.0% medp25 50.0% · p75 50.0%top quartile

Observations

IR observations

Last actual EPS-65.51 JPY

Last actual revenue13,005,130,000 JPY

Source data

Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.

Company fundamentalsperiod FQ-7 · history via verified-market-data

no public URL

2026-05-03 17:30 UTC#3a7e4581

Source: analysis-pipeline (hybrid)Generated: 2026-05-03 17:32 UTCJob: c69bb2da